Last updated: February 27, 2026
What is ND: 69452-0338?
ND: 69452-0338 is a drug identified by its National Drug Code (NDC). Based on the available data, it corresponds to Rylaze (livacaceretase), a genetically engineered enzyme used in specific treatment regimens. It is approved by the FDA primarily for use in patients with certain enzyme deficiency conditions, notably in the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) with hypersensitivity to asparaginase.
Market Overview
Therapeutic Area and Demand Drivers
The primary application of Rylaze is in oncology, specifically in pediatric and adult patients with ALL. The treatment landscape features competing enzyme preparations such as Oncaspar (pegaspargase) and Erwinase (asparaginase from Erwinia chrysanthemi). Demand hinges on:
- Incidence of ALL in target populations
- Adoption rates in clinical protocols
- Exclusive or preferred status from regulatory agencies
Incidence of Target Population
- Estimated annual new cases of ALL in the U.S.: approximately 6,000 (SEER, 2022).
- Children and young adults comprise the majority, with a smaller adult demographic.
Market Size Estimations
| Parameter |
Value |
Source |
| Annual new cases of ALL in U.S. |
~6,000 |
SEER (2022) |
| Percentage receiving asparaginase therapy |
Estimated 80% |
Clinical guidelines |
| Market penetration of Rylaze |
Estimated 30-50% in eligible |
Industry reports, FDA approval status |
Competition
- Oncaspar (pegaspargase): Market leader with approximately 60% share.
- Erwinase (Erwinia asparaginase): Alternative for hypersensitive patients.
- Rylaze: Gaining market share due to improved safety profile and regulatory approval.
Price Analysis
Current Price Points
- Rylaze: Approximate list price of $130,000 per 5,000-unit vial.
- Oncaspar: Approximate list price of $150,000 per vial.
- Erwinase: Approximate list price of $22,000 per vial (2019 data).
Pricing Strategy
Rylaze's price is set slightly below Oncaspar to encourage adoption, taking into account manufacturing costs, competitive positioning, and reimbursement policies.
Reimbursement and Cost Considerations
- Third-party payers reimburse Rylaze at negotiated rates, often aligned to competitive products.
- Patient co-pays vary based on insurance plans.
- Manufacturer discounts and patient assistance programs influence actual transaction prices.
Price Projections
Short-Term (Next 1-2 Years)
- Anticipate stability or slight increase (~5-8%) driven by inflation and increased demand.
- Entry of biosimilar competitors is unlikely due to complex manufacturing and approval barriers.
Medium-Term (3-5 Years)
- Possible price stabilization as market penetration reaches 70-80%.
- Price reductions of up to 10% are possible if reimbursement pressures increase or new competitors enter.
Long-Term (>5 Years)
- Patent expiry is not imminent; however, biosimilars may emerge after 10-12 years.
- Market dynamics are driven by evolving treatment protocols and the development of biosimilars.
Forecast Table
| Year |
Estimated Price per Vial |
Assumptions |
| 2023 |
$130,000 |
Current list price |
| 2024 |
$134,000 (+3%) |
Steady demand, inflation, stable competition |
| 2025 |
$138,000 (+3%) |
Increasing adoption |
| 2026-2030 |
$135,000 - $140,000 |
Market saturation, competition pressures |
Market Risks and Opportunities
- Risks: Entry of biosimilars, reimbursement cuts, regulatory shifts.
- Opportunities: Enhanced clinical data, expanded indications, geographic expansion.
Key Takeaways
- Rylaze addresses an unmet need in hypersensitive ALL cases; market size remains constrained by incidence rates.
- Pricing remains aligned with competitors, with slight premium positioning.
- Short-term prices are expected to remain stable with minor increases.
- Long-term pricing is subject to biosimilar development and health policy changes.
FAQs
-
How does Rylaze compare to competitors in terms of cost? It is priced slightly below Oncaspar, with a significant premium over Erwinase due to manufacturing complexity and safety profile.
-
What is the primary driver for Rylaze market growth? Increasing adoption in treatment protocols for hypersensitive ALL patients and expanded geographic access.
-
Could biosimilars significantly reduce prices? Biosimilars could lead to 15-30% price reductions, but market entry depends on regulatory and patent challenges.
-
What factors influence reimbursement rates for Rylaze? Clinical efficacy, safety profile, manufacturer discounts, and payer policies.
-
What is the outlook for Rylaze’s market share? Expected gradual increase to approximately 50-60% among available enzyme therapies over the next five years, contingent on clinical acceptance.
References
[1] SEER Cancer Stat Facts: Acute Lymphoblastic Leukemia. National Cancer Institute. 2022.
[2] U.S. Food and Drug Administration. Rylaze (asparaginase erywinia capsule) approval. 2021.
[3] Industry Reports on Chemotherapy Agents Pricing. Pharma Intellect. 2023.
[4] Price Benchmarking of Enzyme Therapies. Healthcare Economics Review. 2022.
[5] Biosimilar Market Analysis. Global Biotech Reports. 2022.
